More than half of patients in Qnexa arm of Vivus' phase 2 trial lost 10% or more total body weight

By Lisa Kerner

Erie, Pa., May 10 - Vivus, Inc. said more than half of the obese patients in its Qnexa treatment group experienced 10% or more total body weight loss during a 24-week double-blind, placebo-controlled clinical trial comparing Qnexa, placebo, a phentermine and topiramate.

Qnexa is a proprietary pharmaceutical treatment for weight loss containing low doses of the active ingredients phentermine and topiramate.

Mean weight loss on an intent-to-treat basis in the Qnexa group was 25.1 pounds, compared to 4.8 pounds in the placebo group, according to a company news release.

There were a total of 200 subjects in the four-arm trial, which was conducted by Duke University Medical Center.

Patients in the Qnexa group had a completion rate of 92% versus a completion rate of 62% for the placebo group.

"These results are consistent with the research data that I have generated using this treatment," principal scientist and Qnexa inventor Dr. Thomas Najarian said in the release.

"Qnexa provides synergistic weight loss over the two active agents and is well tolerated."

Vivus is a Mountain View, Calif., pharmaceutical company developing therapeutic products addressing obesity and sexual health.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.